Top

Published in:

Open Access 01-12-2022 | Idiopathic Pulmonary Fibrosis | Research

Plumbagin attenuates Bleomycin-induced lung fibrosis in mice

Authors: Saber Mehdizadeh, Marjan Taherian, Paria Bayati, Kazem Mousavizadeh, Salar Pashangzadeh, Ali Anisian, Nazanin Mojtabavi

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2022

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with limited treatment options. Plumbagin (PL) is an herbal extract with diverse pharmacological effects that have been recently used to treat various types of cancer. This study aims to explore the anti-fibrotic effect of PL and possible underlying mechanisms in IPF.

Methods

We used a bleomycin-induced experimental mouse model of lung fibrosis to assess the potential anti-fibrotic effect of PL. Histological analysis of lung tissue samples by H&E and Masson’s trichrome staining and hydroxyproline assay was performed to evaluate the fibrotic alterations. ELISA and real-time quantitative PCR were conducted to determine the amount of tumor necrosis factor-alpha (TNFα), tumor growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and endothelin-1 (ET-1).

Results

Bleomycin exposure induced lung fibrosis, which was indicated by inflammation, collagen deposition, and structural damage. PL remarkably prevented bleomycin-induced lung fibrosis. Furthermore, PL significantly inhibited TNF-α and TGF-β production. PL also diminished the upregulated expression of CTGF and ET-1 induced by bleomycin.

Conclusion

Overall, our findings suggest PL as an anti-fibrotic agent acting via down-regulation of TGF-β/CTGF or ET-1 axis, as well as TNF-α, to improve lung fibrosis.

Zolak JS, de Andrade JA. Idiopathic pulmonary fibrosis. Immunol Allergy Clin North Am. 2012;32(4):473–85.PubMedCrossRef

Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2(2):103–21.PubMedPubMedCentralCrossRef

Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–51.PubMedCrossRef

Navaratnam V, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorac Surg Clin. 2011;66(6):462–7.

Raimundo K, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16(1):2.PubMedPubMedCentralCrossRef

Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.PubMedCrossRef

Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.PubMedCrossRef

King TE Jr, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.PubMedCrossRef

Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.PubMedCrossRef

10.

Parimala R, Sachdanandam P. Effect of Plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma. Mol Cell Biochem. 1993;125(1):59–63.PubMedCrossRef

11.

Xu TP, et al. Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14(4):2325–31.PubMedCrossRef

12.

Checker R, et al. Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol. 2009;9(7–8):949–58.PubMedCrossRef

13.

Wei Y, et al. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells. Oncotarget. 2017;8(9):15230–41.PubMedPubMedCentralCrossRef

14.

Liu Y, et al. Anticancer Properties and Pharmaceutical Applications of Plumbagin: A Review. Am J Chin Med. 2017;45(3):423–41.PubMedCrossRef

15.

Panichayupakaranant P, Ahmad MI. Plumbagin and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016;929:229–46.PubMedCrossRef

16.

Zhang K, et al. Plumbagin suppresses dendritic cell functions and alleviates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;273(1–2):42–52.PubMedCrossRef

17.

Chen S, et al. Plumbagin ameliorates CCl4-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway. Evid Based Complement Altern Med. 2015.

18.

Wang H, et al. Plumbagin protects liver against fulminant hepatic failure and chronic liver fibrosis via inhibiting inflammation and collagen production. Oncotarget. 2016;7(50):82864–75.PubMedPubMedCentralCrossRef

19.

Chen Y, et al. Plumbagin ameliorates liver fibrosis via a ROS-mediated NF-кB signaling pathway in vitro and in vivo. Biomed Pharmacother. 2019;116:108923.PubMedCrossRef

20.

Wei Y, et al. Anti-fibrotic effect of plumbagin on CCl₄-lesioned rats. Cell Physiol Biochem. 2015;35(4):1599–608.PubMedCrossRef

21.

Carrington R, et al. Use of animal models in IPF research. Pulm Pharmacol Ther. 2018;51:73–8.PubMedCrossRef

22.

Yan W, et al. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice. Acta Pharmacol Sin. 2014;35(1):124–34.PubMedPubMedCentralCrossRef

23.

Niu M, et al. Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression. J Pharmacol Sci. 2015;128(3):131–6.PubMedCrossRef

24.

Rayamajhi M, et al. Non-surgical intratracheal instillation of mice with analysis of lungs and lung draining lymph nodes by flow cytometry. J Vis Exp. 2011(51).

25.

Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta. 1967;18(2):267–73.PubMedCrossRef

26.

Moore B, et al. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167–79.CrossRef

27.

Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis—past, present and future. Respir Med. 2006;100(11):1871–85.PubMedCrossRef

28.

Li X, et al. Drugs and targets in fibrosis. Front Pharmacol. 2017;8:855.PubMedPubMedCentralCrossRef

29.

Piguet PF, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170(3):655–63.PubMedCrossRef

30.

Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorac Surg Clin. 1993;48(10):959–66.

31.

Palanisamy N, Kannappan S, Anuradha CV. Genistein modulates NF-κB-associated renal inflammation, fibrosis and podocyte abnormalities in fructose-fed rats. Eur J Pharmacol. 2011;667(1–3):355–64.PubMedCrossRef

32.

Lasky JA, Brody AR. Interstitial fibrosis and growth factors. Environ Health Perspect. 2000;108(Suppl 4):751–62.PubMedPubMedCentralCrossRef

33.

Mahendran S, Sethi T. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? QJM. 2012;105(10):929–34.PubMedCrossRef

34.

Leask A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal. 2011;5(2):125–9.PubMedPubMedCentralCrossRef

35.

Zhu B, et al. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci. 2013;14(12):24476–91.PubMedPubMedCentralCrossRef

36.

Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88(2):163–6.PubMedPubMedCentralCrossRef

37.

Jacobson A, Cunningham JL. Connective tissue growth factor in tumor pathogenesis. In Fibrogenesis & tissue repair. BioMed Central. 2012.

38.

Tzortzaki EG, et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med. 2007;101(8):1821–9.PubMedCrossRef

39.

Abraham D. Role of endothelin in lung fibrosis. Eur Respir Rev. 2008;17(109):145–50.CrossRef

40.

Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S93-7.PubMed

41.

Lee SY, et al. Plumbagin suppresses pulmonary fibrosis via inhibition of p300 histone acetyltransferase activity. J Med Food. 2020;23(6):633–40.PubMedCrossRef

Title: Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Authors: Saber Mehdizadeh
Marjan Taherian
Paria Bayati
Kazem Mousavizadeh
Salar Pashangzadeh
Ali Anisian
Nazanin Mojtabavi
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Idiopathic Pulmonary Fibrosis
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2022
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-022-00734-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plumbagin attenuates Bleomycin-induced lung fibrosis in mice

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis

Systemic lupus erythematosus with various clinical manifestations in a patient with hereditary angioedema: a case report

The association between early formula and reduced risk of cow’s milk allergy during the first three year of life: a Japanese cohort study

Generalized allergic reaction in response to exercise due to strawberry gibberellin-regulated protein: a case report

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases

Allergic rhinitis, allergic contact dermatitis and disease comorbidity belong to separate entities with distinct composition of T-cell subsets, cytokines, immunoglobulins and autoantibodies